Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
115
resultados
Última actualización
19/10/2024 [06:51:00]
Resumen de: US2024343760A1
Disclosed herein are peptides useful for targeting the retina, and may be useful for targeting specific cells in the retina. The peptides may have a Formula I or V:R1—X1—X2—(X3)n—X4—X5—X6—X7—R2 Formula IR1-Asn-Val-Ser-Ala-Tyr-Pro-Thr-R2 Formula V.Also disclosed are conjugates and compositions comprising the peptides. The compositions may comprise a desired agent to be delivered to the retina, such as a therapeutic agent and/or an imaging agent. Methods for administering the peptide, conjugates, and/or composition to a subject also are disclosed.
Resumen de: US2024343701A1
The present application disclosed a compound of formula (I) and a salt and a stereoisomer thereof, wherein each variable is as defined in the specification. The present application also disclosed a nanoparticle composition comprising the compound or a salt or a stereoisomer thereof, and the use of the nanoparticle composition for delivering active agents.
Resumen de: US2024344068A1
Disclosed herein are siRNAs, hybrid nanoparticles comprising the siRNAs, pharmaceutical compositions comprising the same, and methods of making and using the same to treat neurological diseases and disorders.
Resumen de: CN118434445A
Disclosed herein are mannan nanogels that are novel vaccine delivery platforms, as well as novel methods of making self-assembled mannan nanogels for the delivery of therapeutic agents in vivo.
Resumen de: WO2023107400A1
Disclosed herein are diamino lipid (dal) compounds and pharmaceutical compositions including mRNA encoding an immunotherapeutic agent and methods of making and use thereof. Also disclosed herein are diamino lipid (DAL) nanoparticles. These nanoparticles can encapsulate a nucleic acid, such as an mRNA, for example. This mRNA can encode a cytokine, such as IL-12, IL-27 and GM-CSF. Also disclosed are methods of treating a subject in need thereof, such as a subject with cancer.
Resumen de: EP4445896A1
The present invention relates to a nanosuspension formulation suitable for a progerinin drug, which is insoluble, and a preparation method therefor. Specifically, the progerinin nanosuspension according to the present invention is a vehicle composition for improving dispersive stability of a progerinin drug(a), which is insoluble, and employs hydroxypropylmethyl cellulose (HPMC)(b) or hydroxypropyl cellulose (HPC)(b'), TPGS(c) or sodium dioctyl succinate (DOSS)(c'), and potassium sorbate(d). A mixture thereof was subjected to wet-type ball milling in a Dyno-Mill chamber to prepare a white nanosuspension containing a progerinin drug with an average particle diameter of 100 nm to 300 nm. This nanosuspension exhibits uniform dispersibility of progerinin drug particles, minimal change in the size of drug particles even at low temperatures or severe environments, and excellent bioabsorption efficiency of the drug. Therefore, it can be widely used as an oral nanosuspension formulation to confirm the therapeutic effect of progeria.
Resumen de: WO2023108013A1
Provided herein are compositions and methods for preventing or reducing CARPA in a subject in need thereof. In one aspect, the composition comprises a therapeutic molecule, diagnostic molecule, molecular complex, or nanoparticle having a complement inhibitory protein attached thereto.
Resumen de: WO2023104380A1
The present invention relates to nanocontainers for the synergistic transport of lipophilic and hydrophilic active substances or detection reagents. In particular, the nanocontainers according to the invention offer a possibility for the diagnostics and/or treatment of diseases with combinations of active substances (therapy) and detection reagents (diagnostics) which can have different solubility properties. The present invention also relates to a method for producing the nanocontainers according to the invention.
Resumen de: EP4445955A2
Provided herein are methods and compositions and kits related to uricase compositions and/or compositions comprising synthetic nanocarriers comprising an immunosuppressant. Also provided herein are methods and compositions and kits for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.
Resumen de: WO2023108111A2
Provided herein are branched BAE/BTE -containing polymers useful as vehicles for the delivery of therapeutic agents, such as nucleic acids. The polymers form stable compositions and are suitable for the delivery of therapeutic agents via nebulization. Compositions of the disclosed polymers are capable of delivering therapeutic agents such as mRNA to lung epithelial cells.
Resumen de: WO2023104227A1
The present invention discloses ginsenosides used alone or in combination with nucleoside/nucleotide analogues for use in the treatment or prophylaxis of chronic hepatitis B virus infections.
Resumen de: MX2024007047A
The disclosure relates to the method of lyophilizing RNA and mixing with a liquid LNP solution, e. g., to make an RNA vaccine or therapeutic. Included are methods for preparing and administering the vaccine or therapeutic.
Resumen de: US2024226300A1
This disclosure relates to the use of an oxygen-containing liquid as a counter measure against vesicants.
Resumen de: CN118369308A
The present disclosure provides novel lipids and compositions comprising the lipids. Lipid nanoparticles (e.g., empty LNP or loaded LNP) include novel cationic lipids and additional lipids such as ionizable lipids, phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) that also include therapeutic and/or prophylactic agents such as RNA may be used to deliver therapeutic and/or prophylactic agents to mammalian cells or organs, for example to modulate polypeptide, protein or gene expression.
Resumen de: CA3240179A1
Nanoparticles useful for drug delivery are described. In one aspect, the nanoparticles contain poly(amine-co-ester)s or poly(amine-co-amide)s (PACE) modified with poly(ethylene glycol) (PACE-PEG), and can be optionally blended with a second PACE polymer optionally containing endgroup modifications. In another aspect, the nanoparticles contain a core containing a PACE polymer optionally containing endgroup modifications, and a polymeric surfactant non-covalently conjugated to the surface of the nanoparticles. The nanoparticles contain a peptide or protein targeting moiety that is covalently conjugated to the PACE-PEG polymer or to the surfactant on the surface of the nanoparticles via a linkage that contains a succinimide or substituted sulfone moiety, respectively. The nanoparticles provide as a versatile platform for the delivery of nucleic acids, such as mRNA.
Resumen de: CA3240179A1
Nanoparticles useful for drug delivery are described. In one aspect, the nanoparticles contain poly(amine-co-ester)s or poly(amine-co-amide)s (PACE) modified with poly(ethylene glycol) (PACE-PEG), and can be optionally blended with a second PACE polymer optionally containing endgroup modifications. In another aspect, the nanoparticles contain a core containing a PACE polymer optionally containing endgroup modifications, and a polymeric surfactant non-covalently conjugated to the surface of the nanoparticles. The nanoparticles contain a peptide or protein targeting moiety that is covalently conjugated to the PACE-PEG polymer or to the surfactant on the surface of the nanoparticles via a linkage that contains a succinimide or substituted sulfone moiety, respectively. The nanoparticles provide as a versatile platform for the delivery of nucleic acids, such as mRNA.
Resumen de: CN118382465A
The present invention is a method and device for treating solid tumors using a shear thinning biomaterial composition containing a beta or alpha emitting radiation source, a polymer matrix, and/or a radiopaque agent. The novel radioactive composition disclosed by the invention can be injected into a target environment percutaneously or through a transcatheter vascular route for local treatment. The invention comprises a shear thinning biological material which, when combined with a radioisotope source, can provide a therapeutic dose of radiation to the local part of a tumor, thereby minimizing the risk of damage to surrounding tissues. The device not only can be used for treating primary tumor, but also can be used for treating residual cancer cells after the primary tumor is cut off. The present invention provides a method of making a shear-thinned radiobiomaterial composition, and a method of utilizing the composition as part of a therapeutic method.
Resumen de: US2023084932A1
This invention relates to methods of preparing nanotherapeutic compounds and compositions comprising nanotherapeutic compounds. The nanotherapeutic compounds prepared according to the methods provided herein are useful for the treatment of disease, for example, cancer, in a subject in need thereof.
Resumen de: CN118766868A
本发明公开了一种载siRNA的纳米复合物及其制备方法与应用，属于生物医学技术领域。其制备方法包括以下步骤：将4‑羧苯基硼酸溶于溶剂，然后加入PEI进行活化，最后与支化聚乙烯亚胺混合，调节pH，搅拌反应，透析，得到苯硼酸接枝聚乙烯亚胺；将所得苯硼酸接枝聚乙烯亚胺和甘露糖于缓冲液中搅拌，透析，得到交联聚阳离子聚合物，将所得交联聚阳离子聚合物配制成交联聚阳离子聚合物溶液，与siRNA溶液混合，搅拌，孵育，制得。本发明制得的纳米复合物具有低毒性、高稳定性，能够有效被细胞摄取，起到对肝癌细胞的蛋白表达、细胞增殖、细胞迁移与侵袭、受体表达的抑制作用，有效的将siRNA富集在肿瘤区域，起到治疗肿瘤的效果。
Resumen de: CN118766867A
本发明属于生物医药技术领域，公开了一种生物活性大分子的纳米细胞内递送体系及其制备方法和基于其的载药纳米复合材料与在制备骨修复材料中的应用。本发明提供一种生物活性大分子的纳米递送体系，包括金属有机框架负载体和无定形磷酸钙包裹层构成。本发明还提供一种基于上述纳米递送体系的载药纳米复合材料，其既可大量负载生物活性大分子，又能透过细胞膜进入细胞内实现胞内药物递送；且核壳结构的相互作用可增强材料的稳定性，进一步负载生物活性大分子，延缓药物释放，大大延长药物释放时间可达21天，以实现持久的药物释放效果，可应用于制备骨修复材料中。本发明复合材料制备过程仅使用水作为溶剂，操作简易，安全性高，适合工业化生产。
Resumen de: CA3238846A1
It relates to a polymer comprising a repeating sarcosine-based unit which is covalently attached directly or through a linker to a vitamin E-based moiety, acceptable salts, stereoisomers and mixtures thereof, and to conjugates of formula (II) comprising these polymers. Nutraceutical, pharmaceutical, diagnostic and cosmetic compositions comprising the polymers and/or the conjugates of formula (II), together with acceptable excipients or carriers are also provided, as well as self-assembled particles comprising the polymers and/or the conjugates of formula (II) and optionally agents encapsulated within the self-assembled particles. It also relates to the use of the polysarcosine-vitamin E derivatives and/or their conjugates in medicine and diagnostics, and as solubilizers, absorption and permeation enhancers, emulsifiers or surface stabilizers.
Resumen de: CN118766874A
本发明涉及药物递送技术领域，特别涉及一种吸入式制剂，以及吸入式制剂的迭代优化流程及其在制备治疗呼吸系统和/或肺部疾病药物中的应用。本发明通过选取特定的可电离脂质，并对辅助脂质、结构脂质和PEG‑脂质进行优化筛选，得到可吸入脂质纳米颗粒处方，并对缓冲体系和辅料进行优化筛选，根据优化筛选后的缓冲体系和辅料再研究脂质纳米颗粒的组成与生物活性之间的对应关系，得到优化的吸入式制剂处方，该吸入式制剂能够突破肺部生理屏障，实现向肺部高效递送核酸治疗分子，且兼具良好的耐受雾化剪切破坏性能、生物安全性和转染效率。
Resumen de: CN118786139A
本发明涉及包含结合有膜支架蛋白(membrane scaffold protein)的抗体的抗体结合脂质纳米粒子，更详细地，涉及如下的抗体结合脂质纳米粒子，包含脂质及结合有膜支架蛋白的抗体，因而易于制备，且特异性靶向能力优秀。
Resumen de: CN118767142A
本发明公开了一种含STING激动剂的药物组合物、其制备的双药纳米颗粒及其用途。本发明所述的药物组合物包含STING激动剂和IDO1抑制剂。该药物组合物能够制备成双药纳米颗粒，包载两种治疗药物的纳米载体可以实现大量的细胞内吞，并且可以帮助药物实现溶酶体逃逸，在细胞质中释放STING激动剂和IDO1抑制剂，能够实现STING激动剂和IDO1抑制剂双靶点的联合给药，从而抑制肿瘤生长和转移。因此，本发明双药纳米颗粒能够用于制备药物组合纳米给药系统，用于制备肿瘤治疗制剂。
Nº publicación: CN118750466A 11/10/2024
Solicitante:
中国医科大学
Resumen de: CN118750466A
本发明属于生物医药技术领域，涉及白蛋白负载盐酸小檗胺纳米复合物的制备方法及其应用，特别涉及白蛋白负载盐酸小檗胺纳米复合物的制备和在制备治疗和/或预防癌症药物中的应用。本发明所述的白蛋白负载盐酸小檗胺纳米复合物，包含盐酸小檗胺、血清白蛋白，血清白蛋白和盐酸小檗胺的质量比为1:0.1～0.4，并以血清白蛋白作为载体材料，乙醇作为脱水剂，戊二醛作为交联剂通过去溶剂‑化学交联法制备得到。白蛋白负载盐酸小檗胺纳米复合物具有明显的抗肿瘤活性，可以用于制备抗肿瘤药物。
BOPI
Sede Electrónica
